Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial

Typhoid conjugate vaccine: are we heading towards the elimination of typhoid in endemic countries?

“…The results reported by Nginache Nampota-Nkomba and co-authors 7 are consistent with those of previous clinical trials of Typbar TCV conducted in different regions including sub-Saharan Africa. [8][9][10] In Burkina Faso, a study of concomitant administration of Typbar TCV with measles vaccine among infants aged 9 months reported Vi IgG GMT of 1203•7 ELISA units per mL with 88% seroconversion on day 28 following immunisation.…”

Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children

“…In a population-based immunization campaign in Pakistan in 2018 involving 23,407 children from 6 months to 10 years of age living in high-risk areas TCV demonstrated 95% effectiveness against culture-confirmed S. Typhi and 97% effectiveness against extremely drug resistant (XDR) S. Typhi . 11 In Malawi effectiveness in vaccinees from 9 months to 12 years of age was 80.7%, 12 , 13 and an efficacy of 81.6% was reported among Nepalese children aged 9 months to 16 years. 14 , 15 Subsequently, a two cohort study conducted in Burkina Faso showed Typbar-TCV® can be safely co-administered with measles-rubella (MR) and yellow fever (YF) vaccines at 9 months or with meningococcal A vaccine at 15 months with no immune interference, supporting large-scale uptake in sub-Saharan Africa.…”

XDR Salmonella typhi Warrants Vaccine Use in Asian Pacific Region: Prevention Is Still Better Than Cure

“…4 Thus, with the availability of these low cost, highly effective, and safe TCV, there is growing optimism regarding the elimination of typhoid fever in endemic regions. 3,4 In addition, it is imperative to promote widespread use of the vaccine due to the increasing incidence of extensively drug-resistant (XDR) Salmonella typhi, making available treatment less effective and costly. Typhi isolates are defined as XDR, if they are multidrug resistant, nonsusceptible to fluoroquinolones, and resistant to third-generation cephalosporins, that is, ceftriaxone.…”